Dividends Inside Welcome to Dividends Inside
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Cybin Inc.
HELP
$4.34 (+ $0.12 + 2.84%)
Last updated: Previous Close (2026-05-20)
About the Company
Cybin Inc. is a clinical-stage neuropsychiatry company dedicated to developing psychedelic-based therapeutics to address unmet needs in mental health treatment. Its lead candidate, CYB003, a proprietary deuterated psilocybin analog, is advancing in phase 3 clinical trials for major depressive disorder, including the multinational EMBRACE study approved in Australia and Europe. CYB004, a deuterated DMT molecule, is in phase 2 trials for generalized anxiety disorder, with enrollment recently completed. The pipeline also features investigational compounds like SPL028, an injectable deuterated DMT that completed phase 1 trials, SPL026 for MDD, and CYB005, a phenethylamine derivative in preclinical stages targeting neuroinflammation and central nervous system disorders. Headquartered in Toronto, Ontario, with approximately 50 employees, Cybin Inc. collaborates with partners such as TMS Neurohealth Centers, Kernel, and Segal Trials to advance its research. Founded in 2016 and led by CEO Eric So, the company plays a pioneering role in the emerging field of psychedelic medicine within the biopharmaceutical sector, focusing on innovative solutions for conditions like depression and anxiety.
Price History
Latest News for HELP
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company, is pleased to announce it has appointed Doug Drysdale, currently BetterLife's corporate advisor and formerly CEO of Cybin Inc. ("Cybin") (NYSE: CYBN), as Executive Chairman and Director. At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Phase 3 trials in..
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector SNDL Reported “Particularly Challenging” First Quarter 2026 Financial and Operational Results Vireo Growth Accelerated Expansion with FLUENT Acquisition, Cementing its Florida Ambitions Aurora Cannabis Expanded Global Medical Portfolio with New International Product Launches Key Takeaways; Psychedelic Sector Silo Pharma Sees Momentum as U.S. Accelerates Psychedelic PTSD Treatments Helus Pharma Expanded Veteran […]
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
NEW YORK & TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 28, 2026, by Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP), please note references to Veterans Exploring Treatment Solutions (“VETS”) have been removed from the first, third and fourth paragraphs. The corrected release follows: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health Collaboration with leading mental health organization to support HLP003 Phase 3 recruitment and
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
Eric So, Interim CEO, to appear on panel entitled “The Next Wave of Health Innovation,” on May 4, 2026 NEW YORK and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Eric So, Helus Pharma’s Interim Chief Executive Officer, will be speaking at the 29th Annual Milken Institute Global Conference on a panel entitled “
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
Collaboration with leading mental health organization to support HLP003 Phase 3 recruitment and expand outreach in veteran communities following landmark Executive Order on breakthrough mental health treatments NEW YORK & TORONTO, April 28, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced a collaboration with TARA Mind, which works with
Does Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk?
Earlier this month, Helus Pharma (operating as Cybin) reshaped its leadership by appointing interim CEO Eric So, expanding medical leadership with Dr. Ken Kramer as Senior Vice President of Medical Affairs, and adding renowned experts Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board. By bringing together high-profile figures in biotechnology, CNS drug development, and medical affairs, Helus Pharma is signaling an emphasis on clinically rigorous development of its...